Popular Senolytic Combo Dasatinib Plus Quercetin Worsens Kidney Damage in Study
Widely-used anti-aging drug combination unexpectedly increased kidney injury markers in mice, raising safety concerns for clinical use.
Summary
A new study found that dasatinib plus quercetin (D&Q), a popular senolytic drug combination used to clear aging cells, actually worsened kidney damage in mice with acute kidney injury. The treatment increased harmful biomarkers and inflammatory responses rather than providing protection. This unexpected finding challenges assumptions about D&Q's safety and suggests caution is needed before widespread clinical use in kidney conditions.
Detailed Summary
This study delivers surprising news about dasatinib plus quercetin (D&Q), one of the most studied senolytic drug combinations in longevity research. While D&Q has shown promise in clearing senescent cells and improving various age-related conditions, this research reveals a concerning downside.
Researchers tested D&Q in mice with folic acid-induced acute kidney injury, a standard model for studying kidney damage. Rather than protecting the kidneys as expected, D&Q pretreatment failed to prevent kidney dysfunction and actually made several damage markers worse.
The results were striking: D&Q significantly increased expression of kidney damage biomarkers Lcn2 and Havcr1, elevated p21 (a senescence marker), and boosted inflammatory secretome components. Surprisingly, the treatment didn't reduce senescent cell numbers or restore protective Klotho protein levels.
These findings matter because D&Q is being actively pursued in human clinical trials for various aging-related conditions. The kidney is particularly vulnerable during aging, and acute kidney injury often progresses to chronic disease, especially in older adults.
The study suggests that senolytics may not be universally beneficial and could potentially harm certain organs under stress. This doesn't invalidate senolytic research entirely, but highlights the need for careful tissue-specific and context-dependent evaluation before clinical translation.
Key Findings
- D&Q pretreatment failed to prevent kidney dysfunction in acute injury model
- Treatment increased kidney damage biomarkers Lcn2 and Havcr1 expression
- D&Q elevated inflammatory secretome components rather than reducing them
- Senescent cell numbers remained unchanged despite senolytic treatment
- Protective Klotho protein levels were not restored by D&Q therapy
Methodology
Researchers used folic acid-induced nephrotoxicity in mice as an acute kidney injury model. D&Q treatment was given as pretreatment, with kidney function and biomarkers assessed at 48 hours post-injury.
Study Limitations
This summary is based on the abstract only, limiting detailed methodology and mechanistic insights. The study used only one acute kidney injury model, and results may not apply to other kidney conditions or senolytic combinations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.